Services
What we do
Transforming complex science
into market access outcomes.
We work across the full market access and evidence lifecycle — from early asset strategy through to reimbursement and launch. Six connected practice areas, delivered senior-led, AI-enabled, and built around the asset and the markets in scope.
Strategy & Market Access
Global and regional market access strategy, pricing and launch sequencing, competitive landscape, payer research, and due diligence. Includes international reference pricing (IRP) simulation and optimised launch sequencing to protect price corridors across markets.
- Global & regional market access strategy
- Pricing strategy & launch sequencing
- International reference pricing (IRP) simulation
- Competitive landscape & payer research
- Commercial due diligence
Health Economics & Evidence
Cost-effectiveness models, budget impact models, evidence generation plans, and real-world evidence strategy. Built to withstand HTA scrutiny. Includes PICO alignment — predicting the population, intervention, comparator, and outcomes that HTA bodies will demand, ahead of submission.
- Cost-effectiveness & budget impact models
- Evidence generation plans & RWE strategy
- PICO alignment ahead of submission
- Synthetic control arms for rare-disease indications
- Burden of illness studies
HTA & Reimbursement
HTA landscape assessments, submission strategy and dossier development, payer engagement and advisory boards, reimbursement negotiation support. Fluent in the regulatory–HTA "double gate" — ensuring data generated for FDA/EMA also satisfies payer value requirements, including the EU Joint Clinical Assessment (JCA).
- HTA landscape assessments & strategy
- Dossier development (NICE, CADTH, HAS, G-BA, AIFA, PBAC, JCA)
- Payer engagement & advisory boards
- Reimbursement negotiation support
- Regulatory–HTA evidence alignment ("double gate")
Value Communication
Global Value Dossiers, value proposition development, payer communication materials, and scientific publications strategy. Moving beyond static documents toward evidence packages that can be updated as new real-world data emerges.
- Global Value Dossiers (GVDs) & payer materials
- Value proposition & messaging development
- Scientific publications strategy
- Dynamic value packages updated as RWE emerges
- Stakeholder-specific communication
Project & Delivery Management
End-to-end project management, cross-functional workshop facilitation, and training. On time, on scope, on budget. Every engagement runs against a defined plan with weekly review calls, structured interim reports, and immediate escalation of any scope, timeline, or quality risk.
- End-to-end project management
- Cross-functional workshop facilitation
- Capability training & team development
- Standard 8 / 12 / 16-week engagement structures
- Risk & issue management with audit trail
AI Enablement
AI-based solution development, AI strategy definition, operational execution, and training. Embedding capability across teams so AI becomes the operating model — not just a tool. We deploy validated, enterprise-grade platforms across the evidence and market access lifecycle, not generic AI applied to specialist problems.
- AI solution development & integration
- AI strategy definition & readiness assessment
- Operational execution & workflow embedding
- Team capability training
- Governance, audit trail, and compliance design
Where we work
Rare. Oncology. Cardiovascular. MedTech.
Deep expertise across the indications where market access is hardest — and across the markets where evidence and pricing decisions actually land.
Rare & ultra-rare disease
12+ indications including FOP, gMG, AML, PNH, aHUS, PKU, gPP. Synthetic control arms and burden of illness studies where traditional RCTs are not feasible.
Oncology
Solid tumours, haematological malignancies, targeted therapies, and emerging immuno-oncology assets across global markets.
Cardiovascular, CNS, autoimmune, infectious disease
Broad therapy area capability supported by our global advisor network and specialist clinical KOLs across each domain.
Medical technology
Robotic surgery, implantable devices, cardiac rhythm management, and haemodynamic monitoring — across pharma, biotech, and medtech sponsors.
Working on a market access challenge?
Every engagement begins with a direct conversation with the senior practitioner who will lead it.
Book a 30-minute call